TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.460nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 36nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 55nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 78nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 130nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
Affinity DataIC50: 250nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 250nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 367nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 394nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 460nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 470nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
Affinity DataIC50: 546nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 700nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 787nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 790nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 810nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 856nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 1.55E+3nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Johnson& Johnson, Pharmaceutical Research and Development, L.L.C.
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
Affinity DataIC50: 2.39E+3nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 2.44E+3nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 2.60E+3nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 2.70E+3nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 2.70E+3nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 2.83E+3nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 3.60E+3nMpH: 7.5 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40E+3nMpH: 7.4 T: 2°CAssay Description:Test compound was incubated for 15 minutes with 30 nM peptide fluorescein-FMDYWEGLN (Fl 9mer) and 120 nM (glycine-HDM2 17-125) in assay buffer. The p...More data for this Ligand-Target Pair
![](/img/powered_by_small.gif)